File Download

  • Find it @ UNIST can give you direct access to the published full text of this article. (UNISTARs only)
Related Researcher

서판길

Suh, Pann-Ghill
Read More

Views & Downloads

Detailed Information

Cited time in webofscience Cited time in scopus
Metadata Downloads

Full metadata record

DC Field Value Language
dc.citation.endPage 2290 -
dc.citation.number 9 -
dc.citation.startPage 2276 -
dc.citation.title LEUKEMIA -
dc.citation.volume 33 -
dc.contributor.author Follo, Matilde Y. -
dc.contributor.author Pellagatti, Andrea -
dc.contributor.author Armstrong, Richard N. -
dc.contributor.author Ratti, Stefano -
dc.contributor.author Mongiorgi, Sara -
dc.contributor.author De Fanti, Sara -
dc.contributor.author Bochicchio, Maria Teresa -
dc.contributor.author Russo, Domenico -
dc.contributor.author Gobbi, Marco -
dc.contributor.author Miglino, Maurizio -
dc.contributor.author Parisi, Sarah -
dc.contributor.author Martinelli, Giovanni -
dc.contributor.author Cavo, Michele -
dc.contributor.author Luiselli, Donata -
dc.contributor.author McCubrey, James A. -
dc.contributor.author Suh, Pann-Ghill -
dc.contributor.author Manzoli, Lucia -
dc.contributor.author Boultwood, Jacqueline -
dc.contributor.author Finelli, Carlo -
dc.contributor.author Cocco, Lucio -
dc.date.accessioned 2023-12-21T18:42:17Z -
dc.date.available 2023-12-21T18:42:17Z -
dc.date.created 2019-10-01 -
dc.date.issued 2019-09 -
dc.description.abstract Specific myeloid-related and inositide-specific gene mutations can be linked to myelodysplastic syndromes (MDS) pathogenesis and therapy. Here, 44 higher-risk MDS patients were treated with azacitidine and lenalidomide and mutations analyses were performed at baseline and during the therapy. Results were then correlated to clinical outcome, overall survival (OS), leukemia-free-survival (LFS) and response to therapy. Collectively, 34/44 patients were considered evaluable for response, with an overall response rate of 76.25% (26/34 cases): 17 patients showed a durable response, 9 patients early lost response and 8 patients never responded. The most frequently mutated genes were ASXL1, TET2, RUNX1, and SRSF2. All patients early losing response, as well as cases never responding, acquired the same 3 point mutations during therapy, affecting respectively PIK3CD (D133E), AKT3 (D280G), and PLCG2 (Q548R) genes, that regulate cell proliferation and differentiation. Moreover, Kaplan-Meier analyses revealed that this mutated cluster was significantly associated with a shorter OS, LFS, and duration of response. All in all, a common mutated cluster affecting 3 inositide-specific genes is significantly associated with loss of response to azacitidine and lenalidomide therapy in higher risk MDS. Further studies are warranted to confirm these data and to further analyze the functional role of this 3-gene cluster. -
dc.identifier.bibliographicCitation LEUKEMIA, v.33, no.9, pp.2276 - 2290 -
dc.identifier.doi 10.1038/s41375-019-0416-x -
dc.identifier.issn 0887-6924 -
dc.identifier.scopusid 2-s2.0-85061772096 -
dc.identifier.uri https://scholarworks.unist.ac.kr/handle/201301/33041 -
dc.identifier.url https://www.nature.com/articles/s41375-019-0416-x -
dc.identifier.wosid 000484399300012 -
dc.language 영어 -
dc.publisher NATURE PUBLISHING GROUP -
dc.title Response of high-risk MDS to azacitidine and lenalidomide is impacted by baseline and acquired mutations in a cluster of three inositide-specific genes -
dc.type Article -
dc.description.isOpenAccess TRUE -
dc.relation.journalWebOfScienceCategory Oncology; Hematology -
dc.relation.journalResearchArea Oncology; Hematology -
dc.type.docType Article -
dc.description.journalRegisteredClass scie -
dc.description.journalRegisteredClass scopus -
dc.subject.keywordPlus MYELODYSPLASTIC SYNDROMES -
dc.subject.keywordPlus NUCLEAR PI-PLCBETA1 -
dc.subject.keywordPlus CELL-GROWTH -
dc.subject.keywordPlus PHASE-II -
dc.subject.keywordPlus DIFFERENTIATION -
dc.subject.keywordPlus COMBINATION -
dc.subject.keywordPlus INVOLVEMENT -
dc.subject.keywordPlus ACTIVATION -
dc.subject.keywordPlus EVOLUTION -
dc.subject.keywordPlus THERAPY -

qrcode

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.